MPLT
MapLight Therapeutics, Inc.
Latest Form 4:Sale$277KbyLillie James Woodruff (Chief Scientific Officer) · filed Aug 5, 2026
MapLight Therapeutics, Inc. (MPLT) has 72 SEC Form 4 filings (184 transaction rows) in the rolling window, disclosed by 12 distinct insiders. Most recent filing: Aug 19, 2026.
The most active filer is Chief Executive Officer Kroeger Christopher A. with 12 filings. Insiders have net sold $27.7M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Christopher A. Kroeger
- Employees:109
- HQ:Redwood City, CA, US
- IPO:2025-10-24
Insider Buying
$17.0M
reported purchases (SEC code P)
Insider Selling
$29.0M
reported sales (SEC code S)
Unique Insiders
12
in the rolling window
Market Cap
$570.5M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 22,082 | $277K | Aug 5 | SEC ↗ | |
Cox TroyFirst filing | Director | Purchase | 15,620 | $149K | Jul 29 | SEC ↗ |
| CAO and Interim CFO | Sale | 10,055 | $367K | Jul 20 | SEC ↗ | |
| CAO and Interim CFO | Sale | 8,455 | $311K | Jul 20 | SEC ↗ | |
| CAO and Interim CFO | Sale | 18,469 | $694K | Jul 20 | SEC ↗ | |
| Chief Discovery Officer | Sale | 10,055 | $367K | Jul 20 | SEC ↗ | |
| Chief Discovery Officer | Sale | 9,056 | $333K | Jul 20 | SEC ↗ | |
| Chief Discovery Officer | Sale | 17,173 | $646K | Jul 20 | SEC ↗ | |
| Chief Executive Officer | Sale | 61,778 | $2.3M | Jul 18 | SEC ↗ | |
| Chief Executive Officer | Sale | 69,082 | $2.5M | Jul 18 | SEC ↗ | |
| Chief Executive Officer | Sale | 16,779 | $636K | Jul 18 | SEC ↗ | |
| Chief Scientific Officer | Sale | 7,643 | $281K | Jul 18 | SEC ↗ | |
| Chief Scientific Officer | Sale | 8,547 | $314K | Jul 18 | SEC ↗ | |
| Chief Scientific Officer | Sale | 2,077 | $79K | Jul 18 | SEC ↗ | |
| General Counsel | Sale | 7,260 | $266K | Jul 18 | SEC ↗ | |
| General Counsel | Sale | 8,118 | $299K | Jul 18 | SEC ↗ | |
| General Counsel | Sale | 1,130 | $43K | Jul 18 | SEC ↗ | |
| Chief Medical Officer | Sale | 28,455 | $1.0M | Jul 18 | SEC ↗ | |
| Chief Medical Officer | Sale | 15,047 | $553K | Jul 18 | SEC ↗ | |
| Chief Medical Officer | Sale | 3,656 | $139K | Jul 18 | SEC ↗ | |
| Chief Executive Officer | Sale | 118,235 | $3.2M | May 19 | SEC ↗ | |
| General Counsel | Sale | 13,917 | $419K | May 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,100 | $576K | May 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 34,411 | $953K | May 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 13,980 | $421K | May 12 | SEC ↗ | |
| Chief Medical Officer | Sale | 4,438 | $127K | May 12 | SEC ↗ | |
| Chief Scientific Officer | Sale | 721 | $20K | May 12 | SEC ↗ | |
| Chief Financial Officer | Sale | 14,904 | $419K | May 7 | SEC ↗ | |
| Chief Financial Officer | Sale | 10,903 | $307K | May 7 | SEC ↗ | |
| Chief Financial Officer | Sale | 10,564 | $298K | May 7 | SEC ↗ | |
| Chief Medical Officer | Sale | 15,652 | $438K | May 7 | SEC ↗ | |
| Chief Medical Officer | Sale | 10,576 | $298K | May 7 | SEC ↗ | |
| Chief Medical Officer | Sale | 24,052 | $692K | May 7 | SEC ↗ | |
| Chief Scientific Officer | Sale | 15,801 | $442K | May 7 | SEC ↗ | |
| Chief Scientific Officer | Sale | 11,095 | $313K | May 7 | SEC ↗ | |
| Chief Scientific Officer | Sale | 24,811 | $714K | May 7 | SEC ↗ | |
| General Counsel | Sale | 13,917 | $388K | May 7 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,571 | $435K | May 7 | SEC ↗ | |
| Chief Executive Officer | Sale | 10,472 | $295K | May 7 | SEC ↗ | |
| Chief Executive Officer | Sale | 23,701 | $682K | May 7 | SEC ↗ | |
| CAAO and PAO | Sale | 51,900 | $1.5M | Apr 29 | SEC ↗ | |
| CAAO and PAO | Sale | 17,935 | $544K | Apr 29 | SEC ↗ | |
| Chief Discovery Officer | Sale | 45,422 | $1.3M | Apr 29 | SEC ↗ | |
Setia VishwasFirst filing | Chief Financial Officer | Sale | 2,806 | $75K | Apr 17 | SEC ↗ |
Setia VishwasFirst filing | Chief Financial Officer | Sale | 116 | $3K | Apr 17 | SEC ↗ |
Kroeger Christopher A.First filing | Chief Executive Officer | Sale | 9,135 | $246K | Apr 17 | SEC ↗ |
Kroeger Christopher A.First filing | Chief Executive Officer | Sale | 10,052 | $275K | Apr 17 | SEC ↗ |
Hanson KristopherFirst filing | General Counsel | Sale | 1,529 | $41K | Apr 17 | SEC ↗ |
Hanson KristopherFirst filing | General Counsel | Sale | 298 | $8K | Apr 17 | SEC ↗ |
Foff Erin PennockFirst filing | Chief Medical Officer | Sale | 2,044 | $55K | Apr 17 | SEC ↗ |
Foff Erin PennockFirst filing | Chief Medical Officer | Sale | 1,169 | $32K | Apr 17 | SEC ↗ |
Lillie James WoodruffFirst filing | Chief Scientific Officer | Sale | 1,730 | $46K | Apr 17 | SEC ↗ |
Lillie James WoodruffFirst filing | Chief Scientific Officer | Sale | 2,783 | $76K | Apr 17 | SEC ↗ |
GILLIS JONATHANFirst filing | CAAO and PAO | Sale | 3,590 | $96K | Apr 17 | SEC ↗ |
Kreitzer AnatolFirst filing | Chief Discovery Officer | Sale | 3,316 | $88K | Apr 17 | SEC ↗ |
| Director | Sale | 8,593 | $231K | Apr 17 | SEC ↗ | |
| Director | Sale | 2,195 | $40K | Feb 24 | SEC ↗ | |
| Director | Sale | 11,264 | $207K | Feb 24 | SEC ↗ | |
| Director | Sale | 736 | $13K | Feb 24 | SEC ↗ | |
Pavlov GeorgeFirst filing | Director | Purchase | 10,658 | $186K | Feb 20 | SEC ↗ |
Pavlov GeorgeFirst filing | Director | Purchase | 4,422 | $78K | Feb 20 | SEC ↗ |
Pavlov GeorgeFirst filing | Director | Purchase | 9,920 | $177K | Feb 20 | SEC ↗ |
| Director | Sale | 12,116 | $221K | Feb 18 | SEC ↗ | |
| Director | Sale | 6,622 | $120K | Feb 12 | SEC ↗ | |
| Director | Sale | 241 | $4K | Feb 12 | SEC ↗ | |
Garnett Timothy JohnFirst filing | Director | Purchase | 14,124 | $253K | Feb 12 | SEC ↗ |
| Director | Sale | 7,039 | $127K | Feb 4 | SEC ↗ | |
| Director | Sale | 1 | $18 | Feb 4 | SEC ↗ | |
Malenka Robert C.First filing | Director | Sale | 6,524 | $122K | Jan 30 | SEC ↗ |
Malenka Robert C.First filing | Director | Sale | 21,262 | $394K | Jan 30 | SEC ↗ |
Malenka Robert C.First filing | Director | Sale | 6,612 | $120K | Jan 30 | SEC ↗ |
Novo Holdings A/SFirst filing | 10% Owner | Purchase | 952,941 | $16.2M | Oct 30 | SEC ↗ |
Related companies
MapLight Therapeutics, Inc. is in the Healthcare sector.